Rovalpituzumab tesirine

Generic Name: Rovalpituzumab tesirine

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1613313-09-9

Unique Ingredient Identifier: P256HB60FF

Background: Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Phase 1

Terminated

Conditions: Malignant Melanoma
Medullary Thyroid Cancer
Glioblastoma
Large-Cell Neuroendocrine Carcinoma
Neuroendocrine Prostate Cancer
High Grade Gastroenteropancreatic Neuroendocrine Carcinoma
Other Neuroendocrine Carcinoma
Other Solid Tumors

Interventions: Drug: Rovalpituzumab tesirine
Drug: Dexamethasone

First Posted Date: 2016-03-16

Last Posted Date: 2020-10-19

Lead Sponsor: AbbVie

Target Recruit Count: 200

Registration Number: NCT02709889

Locations: 🇺🇸
Johns Hopkins University /ID# 155412, Baltimore, Maryland, United States
🇺🇸
Virginia Cancer Specialists /ID# 162006, Fairfax, Virginia, United States
🇺🇸
Rutgers Cancer Institute of NJ /ID# 162010, New Brunswick, New Jersey, United States

and more 27 locations

Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Rovalpituzumab tesirine

First Posted Date: 2016-02-04

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie

Target Recruit Count: 342

Registration Number: NCT02674568

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy